Skip to content

Impairment Charges at other companies

Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$12.18M
Sonoco Products logo
Sonoco ProductsSON
$3.09M-37.6%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$15.86M+50.0%

Other financials

Income statement

See full
Revenue$844.9M+21.0%
Gross profit$296.4M+27.8%
Operating income$177.1M+65.5%
Net income$138.8M+54.6%
EPS (diluted)$1.92+56.1%

Balance sheet

See full
Cash & equivalents$521.4M+29.0%
Total debt$321.0M+4.4%
Total equity$3.0B+11.5%
Total assets$4.1B+13.6%

Cash flow

See full
Operating cash flow$89.9M-30.5%
CapEx$42.7M-40.1%
Free cash flow$47.2M-18.8%

Valuation

See full
Market cap$25.36B+64.2%
Enterprise value$25.16B+65.1%
P/E46.7×+15.1×
P/S7.9×+2.7×

Profitability

See full
Gross margin36.3%+1.7pp
Operating margin20.3%+1.2pp
Net margin16.8%+0.7pp
FCF margin14.2%+3.6pp

Returns & leverage

See full
Return on equity19.1%+1.7pp
Debt / equity0.1×0.0×
Current ratio2.7×-0.1×

Where this comes from

Reported directly by West Pharmaceutical Services in its filing.

Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.

The official record: West Pharmaceutical Services’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about West Pharmaceutical Services's impairment charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is West Pharmaceutical Services's impairment charges?
West Pharmaceutical Services (WST) reported impairment charges of $300K in Q1 2026.
How has West Pharmaceutical Services's impairment charges changed year-over-year?
West Pharmaceutical Services's impairment charges decreased by 0.0% year-over-year, from $300K to $300K.
What does impairment charges mean?
Write-downs of long-lived assets (excluding goodwill) when their carrying value exceeds fair value, including property, equipment, right-of-use assets, and other tangible assets.